<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826185</url>
  </required_header>
  <id_info>
    <org_study_id>IMB101-007</org_study_id>
    <nct_id>NCT04826185</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial</brief_title>
  <acronym>IMPROVE-HCM</acronym>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imbria Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imbria Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and potential efficacy of&#xD;
      IMB-1018972 in patients with non-obstructive HCM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs</measure>
    <time_frame>Baseline through Week 14 Safety Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of peak oxygen consumption (VO2) and Oxygen uptake efficiency slope (OUES), measured by standardized cardiopulmonary exercise testing (CPET)</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-obstructive Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>IMB-1018972 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMB-1018972</intervention_name>
    <description>Modified release (MR) oral tablet</description>
    <arm_group_label>IMB-1018972 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European&#xD;
             guidelines&#xD;
&#xD;
          -  Ability to perform an upright treadmill cardiopulmonary exercise test&#xD;
&#xD;
          -  Agreement to abide by contraceptive requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant concurrent condition which could prevent the patient from&#xD;
             performing any of the protocol-specified assessments, represent a safety concern if&#xD;
             the patient participates in the trial or could confound trial assessments of safety or&#xD;
             tolerability&#xD;
&#xD;
          -  Women who are pregnant, planning to become pregnant or lactating&#xD;
&#xD;
          -  Participation in another clinical study involving a test product or invasive medical&#xD;
             device within 28 days (or within 5 elimination half-lives of the respective test&#xD;
             product, whichever is longer), prior to first dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chamberlin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imbria Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Jauregui</last_name>
    <phone>(617) 675-4060</phone>
    <email>HCM_ClinicalTrial@Imbria.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-353-9156</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-926-4000</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-636-8066</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-362-8901</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>917-891-2877</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-373-0212</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-7400</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44 (0) 1865 2 34588</phone>
      <email>HCM_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

